Table 3 Comparison of clinical characteristics between the infusion-related reaction and non-infusion-related reaction groups
IRR group (n = 5) | non-IRR group (n = 8) | p-Value | ||
|---|---|---|---|---|
Patient characteristics | ||||
Age (years) | Median [25, 75%] | 29 [26–30] | 26 [23–31] | 1.0 |
Sex | Male | 3 (60.0%) | 4 (50.0%) | 1.0 a) |
Female | 2 (40.0%) | 4 (50.0%) | ||
Body weight (kg) | Median [25, 75%] | 82.1 [53.0–85.5] | 50.2 [46.1–54.4] | 0.065 |
BSA (m2) | Median [25, 75%] | 1.86 [1.58–2.02] | 1.48 [1.44–1.55] | 0.045 |
BMI (kg/m2) | Median [25, 75%] | 27.7 [19.0–29.2] | 18.5 [17.8–22.8] | 0.093 |
Laboratory data | ||||
White blood cell count (*102/µL) | Median [25, 75%] | 100 [98–114] | 68 [61–88] | 0.067 |
Hemoglobin value (g/dL) | Median [25, 75%] | 13.4 [12.0–15.8] | 14.3 [13.2–14.4] | 0.94 |
Platelet count (*104/µL) | Median [25, 75%] | 31.4 [28.7–44.5] | 26.6 [22.7–32.0] | 0.28 |
Aspartate aminotransferase (U/L) | Median [25, 75%] | 18 [17–18] | 18 [15–21] | 0.82 |
Alanine transaminase (U/L) | Median [25, 75%] | 16 [9–26] | 24 [19–38] | 0.13 |
Serum creatinine (mg/dL) | Median [25, 75%] | 0.73 [0.56–0.84] | 0.72 [0.66–0.79] | 0.88 |
eGFR (mL/min/1.73 m2) | Median [25, 75%] | 103.9 [89.3–107.5] | 92.7 [75.4–102.0] | 0.52 |
Serum albumin (g/dL) | Median [25, 75%] | 4.1 [2.9–4.1] | 3.6 [3.3–3.8] | 0.51 |
Regular use of drugs on the day of rituximab | ||||
Histamine H1 blocker | Yes | 0 (0.0%) | 0 (0.0%) | 1.0 a) |
No | 5 (100%) | 8 (100%) | ||
Histamine H2 blocker | Yes | 2 (40.0%) | 2 (25.0%) | 1.0 a) |
No | 3 (60.0%) | 6 (75.0%) | ||
Analgesic drug | Yes | 0 (0.0%) | 0 (0.0%) | 1.0 a) |
No | 5 (100%) | 8 (100%) | ||
Prednisolone | Yes | 5 (100%) | 8 (100%) | 1.0 a) |
No | 0 (0.0%) | 0 (0.0%) | ||
Cyclosporine | Yes | 4 (80.0%) | 6 (75.0%) | 1.0 a) |
No | 1 (20.0%) | 2 (25.0%) | ||
Mizoribine | Yes | 0 (0.0%) | 1 (12.5%) | 1.0 a) |
No | 5 (100%) | 7 (87.5%) | ||
Mycophenolate mofetil | Yes | 0 (0.0%) | 0 (0.0%) | 1.0 a) |
No | 5 (100%) | 8 (100%) | ||
Prednisolone dosage (mg/day) | Median [25, 75%] | 12.5 [10–30] | 18.8 [13.1–25.0] | 1.0 |
Details of premedication (presence/absence of 4 mg of intravenous betamethasone) | ||||
Presence | 4 (80.0%) | 7 (87.5%) | 1.0 a) | |
Absence | 1 (20.0%) | 1 (12.5%) | ||
Rituximab dosage normalized by BSA | ||||
Dose/BSA (mg/m2) | Median [25, 75%] | 268.8 [247.5–316.5] | 337.9 [322.9–346.8] | 0.045 |